Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/clients/e018409a36d8d382bd5c9d12746db954/sites/oncodesign-joomla.propulse.dev/plugins/system/helix3/core/classes/menu.php on line 89

Integrated Drug Discovery Service (IDDS) becomes DRIVE-IDDS™

DRug Integrative discoVEry |
an integrated drug discovery & development solution from hit finding to IND filing.

The drug discovery process is faced with a growing pressure to deliver novel therapeutic agents faster and with a potential for a lower attrition in the clinic, to treat diseases with high unmet medical needs
For the past 25 years, Oncodesign has been building an integrated drug discovery engine for precision medicine enabling to orient, drive the discovery and deliver pre-clinical candidates successfully.

DRIVE-IDDS™ is part of our continuous improvement in the integrated drug discovery support. It gives access to a comprehensive continuum of technological platforms together with our strategic partners’ complementary expertise. DRIVE-IDDS™ is a smart and agile solution to help clients streamline their drug discovery and development programs and to make best use of their resources and achieve optimum results.

DRIVE-IDDS™ offers a complete drug discovery and development solution through the whole value chain from hit finding to IND filing, aiming to accelerate the entry of the client new chemical entities into clinic within a 3 to 4 years timeframe to deliver an IND.

DRIVE premium solution timeline

Our distinctiveness comes from our expertise in the breadth & depth of innovative service

DRIVE-IDDS™ encompasses all drug discovery skills, expertise & platforms to deliver drug in major therapeutical areas, in oncology, immuno-oncology, infectious disease, immuno-inflammation and inflammation.

DRIVE technological platforms

The quality of the starting hits impacts the future likelihood of success to pre-clinical candidate. Additionally, clients seek for rapid optimization and development cycles from hit finding, hit to lead and drug candidates.

DRIVE-IIDS™ enables our clients, with the best possible options, to identify and validate promising hit series, owing to the innovative technologies provided by our strategic partners: HitGen, 2Bind, Icaria and Iktos.

DRIVE-IDDS™ also, sustains the Hit to Pre-Clinical Candidate process in a Multiparametric optimization mode and with a fast streamlined testing of every newly synthesized compounds. This holds from our experienced multi-disciplinary teams in the drug discovery process, efficiently interacting to allow rapid iteration and results sharing between medicinal chemistry, in vitro and in vivo pharmacology and DMPK.

What can our clients expect from Oncodesign’s DRIVE-IDDS™?

Oncodesign recognizes it is a significant investment for clients to select and access specialized technologies and expert scientist resources with an extensive knowledge of pharmaceutical drug discovery and development. When it comes to outsource client projects, quality, innovation, time and agility are key components for clients seeking to build a trusted and long-term relationship.

Helping our clients identify new approaches and anticipate tomorrow’s challenge

Oncodesign is a vector for therapeutic innovation to help our clients identify new approaches and anticipate tomorrow’s challenge.

We investigated and established the preclinical proof-of concept of a multitude of therapeutic approaches and products, representing more than 5000 advanced preclinical or clinical assets ranging from small molecules and biological entities as well as new therapeutic solutions.

Based on its recognized pharmacological platforms, Predict®, Xmice® and Pharmimage®; Oncodesign advises on, and develops, fit-for-purpose and disease relevant in vitro and in vivo pharmacological models. These include sophisticated humanized models and several translational pharmaco-imaging modalities, to elucidate target engagement, mechanism of action, PK/PD, and therapeutic efficacy investigations, particularly in the therapeutic fields of oncology and autoimmune and inflammatory disorders.

A strong track record

Oncodesign’s multidisciplinary research teams and our seasoned management staff have had true accomplishments in drug discovery, having delivered more than 20 pre-clinical candidates to clients, partners and internally. A significant number of pre-clinical candidates, including first-in-class, have already progressed into clinical trials

Besides, we have been serving more than 800 clients amongst pharmaceutical, biotech and life-science companies around the world to assess numerous treatment options in preclinical proof-of-concept studies across major therapeutic areas.

We also take pride in the trust and fidelity of our clients proven by long-term agreements and sustained repeat business.

Mutual understanding & customized project management

We first listen to and understand clients’ requirements to design tailored drug discovery and development programs. Together, we establish the candidate drug target profile and set key milestones to reach endpoints for activity, selectivity, pharmacological profile and toxicity, within a defined frame time.

To allow our client to take informed and on-time decisions, we implement both steering committees to align common next steps and a program management to insure constructive and regular discussions.

Mutual undertanding communication drug discovery process

A collaborative mindset from a team with mix of backgrounds, experiences & skills

For Oncodesign "we must succeed together". This motto expresses the creation of value arising from reciprocity, that is to say balanced, and transparent exchanges at all levels, with our partners and our clients.

We acknowledge the diversity of our clients’ cultures and needs. However, all clients seek Oncodesign’s team ability to design and perform drug discovery and development program encompass highest pharmaceutical standard to deliver robust data and products. Oncodesign combines a biotechnology mindset to seek for all fast track pathways along with a sense of service to deliver and communicate on purpose.

Our management, scientific and business development teams include a mix of origin, experiences and skills. This diversity is a valuable asset to Oncodesign, allowing us to understand each unique client and to drive discovery programs knowing that no two projects will ever be the same.

Collaborative mindset

Quality meeting client satisfaction & regulatory requirements

Oncodesign’s quality management aims to set-up a framework to monitor our ability to meet client satisfaction in drug discovery and development along with regulatory requirements. Being part of the comprehensive company management, the effectiveness and efficiency our dynamic quality management processes improve it on a continuous basis.

As such, Oncodesign welcomes inspections and audits from clients & health authorities for the work being considered.

Furthermore, for non-clinical development, Oncodesign is GLP compliant with grade A certification from French authorities (ANSM).

We answer your questions

1) How do you coordinate the communication, project design and management across the five partner companies within the DRIVE alliance?

Oncodesign is coordinating and ensuring the smooth integration and continuity of your research and development programs. Each client has a dedicated joint steering committee made up of the senior leaders and scientific directors of the organizations, who will give your project the highest chances of success with their specialized expertise and industry experience. This team supervises the rapid and productive progression of the program phases and achievement of milestones.

The joint steering committee is operationally supported by a central project management (PM) team at Oncodesign, which is fluidly connected to the study directors and managers within each DRIVE partner company. The effective communication and coordination of the project across partners will be governed and overseen by the Oncodesign PM team. 

For different project needs – from Hit-Identification, to Hit-to-Lead, to Lead-to-PCC (preclinical candidate nomination) – the degree of involvement and requirement from each DRIVE partner will vary, regarding project management and contracting. This will be appropriately customized and specified, based on what is best for your project!

2) On a DRIVE project, who owns the IP?
3) Can you elaborate more on the testing techniques employed for binding on-DNA hits?
4) Do you provide services in biologics and protein-based drug discovery?
5) How does Iktos generative modeling work for early stage projects for which not much data is available?
6) Concerning the structure based generative modeling: What docking software do you use, is it a publicly available one or a proprietary one?